115844-00-3

Basic information

• Product Name: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline
• Synonyms: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline;4-bromo-2-chloro-5-(trifluoromethoxy)benzenamine
• CAS NO: 115844-00-3
• Molecular Formula: C₇H₄BrClF₃NO
• Molecular Weight: 290.4649696
• Mol File: 115844-00-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 245.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.812±0.06 g/cm3(Predicted)
• PKA: 0.71±0.10(Predicted)
• CAS DataBase Reference: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline(115844-00-3)
• EPA Substance Registry System: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline(115844-00-3)

Safety Data

• Hazardous Substances Data: 115844-00-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-chloro-5-(trifluoromethoxy)aniline is a chemical compound that has a combination of bromine, chlorine, trifluoromethoxy groups attached to an aniline base. The bromine and chlorine atoms are halogens which typically make the molecule more reactive while the trifluoromethoxy group can contribute to the overall stability of the compound. 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline could be used in various chemical reactions, particularly in organic synthesis, due to its functional groups. Like all aniline derivatives, it must be handled with care due to its potential toxicity. The specific uses for this compound could vary greatly depending on the specific field of study or industry it is used in, from potential pharmaceutical applications to use in material sciences or as a building block in chemical synthesis.

Upstream product

• 116369-25-6 4-bromo-3-(trifluoromethoxy)phenylamine 

Downstream Products

• 1477815-33-0 4-[4-(4-bromo-2-chloro-5-trifluoromethoxyphenylcarbamoyl)piperazin-1-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1477816-25-3 ((S)-1-{(2S,4S)-2-[4-(5'-chloro-4'-{[4-((S)-2-methylpiperazin-1-yl)piperidine-1-carbonyl]amino}-2'-trifluoromethoxybiphenyl-4-yl)-1H-imidazol-2-yl]-4-methylpyrrolidine-1-carbonyl}-2-methylpropyl)carbamic acid methyl ester 
• 1477815-63-6 (S)-4-[1-(4-bromo-2-chloro-5-trifluoromethoxyphenylcarbamoyl)piperidin-4-yl]-3-methylpiperazinecarboxylic acid tert-butyl ester 
• 1476721-09-1 (R)-4-[5-(2-chloro-4-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-3H-naphtho[1,2-d]imidazol-7-yl}-5-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1374892-55-3 N-(4-bromo-2-chloro-5-trifluoromethoxy-phenyl)-6-fluoro-nicotinamide 
• 1433946-60-1 N-{5-chloro-4'-[2-((2S,4S)-4-methoxy-pyrrolidin-2-yl)-1H-imidazol-4-yl]-2-trifluoromethoxy-biphenyl-4-yl}-6-[(R)-4-(2,2-dimethyl-propionyl)-2-methyl-piperazin-1-yl]-nicotinamide 
• 1433281-16-3 N-(5-chloro-4'-(2-((2S,4S)-4-methylpyrrolidin-2-yl)-1H-imidazol-4-yl)-2-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)-6-((R)-2-methyl-4-pivaloylpiperazin-1-yl)nicotinamide 

Relevant articles and documents

NOVEL INHIBITORS OF HEPATITIS C VIRUS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

NOVEL INHIBITORS OF HEPATITIS C VIRUS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.